|Articles|December 1, 2002

FDA Approves ChloraPrep One-Step Sepp Applicator

OVERLAND PARK, Kan. -- Medi-Flex, Inc., announces that its commercial antiseptic ChloraPrep One-Step Sepp applicator (2 percent w/v chlorhexidine gluconate and 70 percent v/v isopropyl alcohol) has been approved for marketing by the United States Food and Drug Administration as a patient pre-operative skin preparation and as a patient pre-injection preparation. The product will be available January 16.

"The introduction of an FDA-approved chlorhexidine skin prep may prove to be the most significant intervention in the prevention of catheter-related bacteremia in the last several decades," said Robert Garcia, BS, MMT (ASCP), CIC and assistant director of infection control at Brookdale University Hospital and Medical Center. "Chlorhexidine's broad antibacterial spectrum and persistent activity after application, in conjunction with no-touch applicators, should provide an effective new tool in the fight against nosocomial infections."

More than 200,000 Americans contract nosocomial infections annually. These preventable infections, which represent the fourth-leading cause of mortality among Americans, cost the healthcare industry billions of dollars and create hardships for both patients and hospitals. One common cause of nosocomial infections are microorganisms found on the patient's skin.

ChloraPrep has been proven to significantly reduce the number of microorganisms on intact skin. It is the only FDA-approved 2 percent w/v chlorhexidine gluconate and 70 percent v/v isopropyl alcohol formulation available in the United States. In addition, ChloraPrep is the only antiseptic that meets new recommendations for skin antisepsis published by the Centers for Disease Control and Prevention (CDC). The CDC guidelines state a preference for a 2 percent chlorhexidine-based antiseptic solution for preparation of the skin prior to catheter insertion.

Studies show that ChloraPrep is effective in killing a broad spectrum of microorganisms on the skin. ChloraPrep is also long lasting. One 30-second application of ChloraPrep is persistent in killing bacteria for more than 48 hours.

Designed for hands-off aseptic application to smaller areas, the 0.67 mL Sepp applicator is the latest in the ChloraPrep line. ChloraPrep is also available in a 1.5 mL Frepp applicator and applicators in the 3.0 mL and 10.5 mL sizes for larger prep sites.

Other ChloraPrep One-Step Sepp product benefits:

-- Unique non-linting tip controls flow, allowing for little excess and no

mess

-- Longer shelf-life ampoule won't dry out like swabsticks or pads

-- Exclusive triple-wall construction for the safest ampoulized applicator

available

-- ChloraPrep is clear, not sticky and doesn't stain the skin

The ChloraPrep One-Step Sepp applicator is the latest product created by Medi-Flex, Inc., an Overland Park, Kan.-based company that manufactures a broad range of aseptic skin prepping products used in hospitals throughout the country.

Source: PRNewswire


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERISS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.